Compare AbbVie Inc (ABBV) vs Snap On Incorporated (SNA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Snap On Incorporated — how do they compare? AbbVie Inc trades at $252.67 (market cap $449.91B), while Snap On Incorporated trades at $400.72 (market cap $21.17B). The key difference: AbbVie Inc is far larger — about 21.3× Snap On Incorporated's market cap, and AbbVie Inc pays the higher dividend (2.72%). Which is the better fit depends on your goals.
| ABBV | SNA | |
|---|---|---|
Market Cap | $449.91B | $21.17B |
Sector | Health | Technology |
52-Week High | $261.07 | $413.62 |
52-Week Low | $184.85 | $313.01 |
Enterprise Value | $513.38B | $20.69B |
Dividend Yield | 2.72% | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.78, down 0.78% on the day, with a bullish technical signal from moving averages and strong institutional support. Recent quarterly earnings have consistently beaten expectations, with Q1 2026 EPS of $2.65 surpassing the $2.59 estimate. Revenue growth is robust, driven by Skyrizi and Rinvoq offsetting Humira declines, though net margins have compressed from 20.38% in 2022 to 6.9% in 2025. Positive news includes phase 2 trial results for ELAHERE in ovarian cancer and sustained dividend payments.
The outlook remains positive with a consensus price target of $266.33 implying ~5% upside, supported by 68% analyst buy ratings. Key risks include patent expirations in the 2030s, margin pressure, and regulatory lawsuits. Cash flow trends show improvement, with 2026 projected net cash flow turning positive to $4.2B, enhancing financial flexibility for growth investments and dividends.
Snap-on Incorporated (SNA) trades at $413.62, up 0.37% with a bullish technical outlook supported by moving averages. The company maintains strong profitability with a 19.6% net income margin and recently beat Q4 2025 earnings. Recent acquisitions like Diesel Laptops for $100 million demonstrate strategic growth initiatives. Analyst consensus is positive with 65% buy ratings and a $407.50 price target.
SNA presents a stable investment with consistent dividend payments and share repurchases, though Q1 2026 earnings miss and elevated valuation ratios pose near-term risks. The stock's technical overbought condition suggests potential consolidation before further upside. Long-term growth depends on successful integration of acquisitions and maintaining premium margins in the competitive tools market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Snap On Incorporated
Snap-on Incorporated is a leading global innovator, manufacturer, and marketer of tools, equipment, diagnostics, repair information, and systems solutions for professional users. Its products are widely used in vehicle service and repair, as well as in other demanding industrial environments. The company is best known for its premium tool brand, often sold through a network of franchised mobile stores, and is a primary supplier to technicians in the transportation industry.
Read more on SNA →
